Weierkang pills for the treatment of moderate to severe chronic atrophic gastritis: a multicentre, large data real-world study

Not Applicable

Recruiting

• Conditions: chronic atrophic gastritis

• Registration Number: ITMCTR2100005255
• Lead Sponsor: Xijing Hospital of Air Force Military Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Age 18-75 years, regardless of gender.
(2) Patients with moderate to severe atrophy and/or intestinalization diagnosed by upper gastrointestinal endoscopy and gastric mucosal pathological tissue biopsy (at least 1 in the gastric sinus and at least 1 in the gastric body) within the last three months, i.e., patients with OLGA/OLGIM stage II-IV (moderate or greater atrophy/atrophy in at least one part of the gastric sinus and body), including those with low-grade intraepithelial neoplasia and those with high-grade intraepithelial neoplasia who do not wish to undergo surgical treatment.
(3) Individuals who have been confirmed free of H. pylori infection or successfully eradicated by 13C-UBT.
(4) Voluntary treatment with Weierkang pills.

Exclusion Criteria

(1) History of previous gastric surgery (including post-ESD, EMR) or with malignancy.
(2) Patients with contraindications to the study drug or allergies to the study drug.
(3) Pregnant and lactating women.
(4) A history of drug abuse or alcohol abuse within the last 1 year.
(5) Those with psychiatric disorders.
(6) Those who are unable to cooperate in completing the treatment protocol
(7) Refusal to sign an informed consent form.
(8) Patients who are participating in other clinical trials.
(9) Patients who, in the opinion of the investigator, are otherwise unsuitable for clinical observational studies.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Histopathological biopsy of gastric mucosa;gastroscopy;

Secondary Outcome Measures

Name	Time	Method
Gastrointestinal symptom Rating Scale;